1. The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)
2. Cavazzoni P. (2022a January). Advancing health through innovation: New drug therapy approvals 2021. Retrieved July 11 2023 from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021
3. Cavazzoni P. (2022b). CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development. Retrieved July 11 2023 from https://www.fda.gov/news-events/fda-voices/cder-continues-make-rare-diseases-priority-drug-approvals-and-programming-speed-therapeutic
4. Center K. L. I. (2018). Regulation on designation of orphan drugs. Retrieved July 6 2023 from https://www.law.go.kr/admRulLsInfoP.do?chrClsCd=010202&admRulSeq=2100000128851
5. Center K. L. I. (2020). Rare disease management Act. Retrieved July 6 from https://www.law.go.kr/LSW//lsInfoP.do?lsiSeq=220907&ancYd=20200811&ancNo=17472&efYd=20200912&nwJoYnInfo=Y&efGubun=Y&chrClsCd=010202&ancYnChk=0#0000